 |
 |

Use of Niacin During NonST-Segment Elevation Acute Coronary Syndromes
 |
 |
| Since this article does not have an abstract, we have provided the first 134 words of the full text and any section headings. |
|
 |
 |
To the Editor: The Clinical Review by Dr Gluckman and colleagues1 on the management of nonST-segment elevation acute coronary syndromes suggests considering the addition of niacin to statins if high-density lipoprotein cholesterol levels are less than 40 mg/dL (1.0 mmol/L) or triglyceride levels are greater than 150 mg/dL (1.7 mmol/L). However, niacin can be dangerous and might even increase myocardial ischemia in the acute setting.2 This may occur on the basis of coronary steal and/or lowering coronary perfusion pressure due to the vasodilating properties of niacin.
Niacin is an excellent lipid-lowering drug to use alone3 or in combination with a statin4 for the prevention of coronary heart disease. However, I believe that if niacin is used, it should never be started during an acute coronary event but should be delayed at least several weeks.
Mark R. Goldstein, MD
markrgoldstein@comcast.net Cleveland Clinic Florida Naples
1. Gluckman TJ, Sachdev M, Schulman SP, Blumenthal RS. A simplified approach to the management of nonST-segment elevation acute coronary syndromes. JAMA. 2005;293:349-357.
FREE FULL TEXT
2. Pasternak RC, Kolman BS. Unstable myocardial ischemia after the initiation of niacin therapy. Am J Cardiol. 1991;67:904-906.
FULL TEXT
|
ISI
| PUBMED
3. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
ABSTRACT
4. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
FREE FULL TEXT
Letters Section Editor: Robert M. Golub, MD, Senior Editor.
JAMA. 2005;293:2092-2093.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|